Domain Therapeutics
@domaintherapeutics.com
Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
Domain Therapeutics's Company Logos
Domain Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#C5C200
Buddha Gold
197, 194, 0
59, 100, 39
0, 2, 100, 23
#73C5F5
Malibu
115, 197, 245
202, 87, 71
53, 20, 0, 4
#00369C
Smalt
0, 54, 156
219, 100, 31
100, 65, 0, 39
About Domain Therapeutics
Domain Therapeutics is a unique biopharmaceutical company located in Strasbourg. They specialize in GPCR (G protein-coupled receptor) in immuno-oncology. With their innovative cancer treatments, they aim to tackle GPCR-mediated immunosuppression and rearm the immune system against tumors.
Their pipeline consists of a range of discovery, candidate, and preclinical phase I programs. These include an A2aR/A2bR antagonist (M1069), an EP4 receptor antagonist (DT-9081), an anti-CCR8 antibody (DT-7012), a PAR2 antagonist (DT-9045), and undisclosed GPCR targets. Domain Therapeutics' unique positioning focuses on building a high-value pipeline centered around GPCRs to effectively reinvigorate the immune system's response to tumors.
They have a press room that showcases their latest news and achievements, including European Patent Office decisions, antibody candidate nominations, and updates on clinical studies. Overall, Domain Therapeutics is committed to revolutionizing cancer treatment through their cutting-edge research and development in immuno-oncology
Company type
Privately Held
Year founded
2008
Company size
51-200 employees
